Acorn Biolabs, a personalized regenerative medicine company, today announced the launch of its Early Access Program through select clinics in North America, marking a major step in the commercialization of its first product in aesthetics. The real-world clinical data obtained through this program will support a broader launch in early 2025.
Acorn’s debut product is a topical skin and haircare treatment developed using a patient’s own hair-follicle stem cells as the source. These cells, which can be easily collected from the patient during an in-office visit, serve as a rich source of proteins, growth factors, peptides and exosomes that are naturally designed to support the skin and hair. This makes these cells an ideal source for personalized regenerative aesthetics products.
“Today is a significant milestone in Acorn’s history as we begin shipping the first personalized products created through our proprietary process for use in the large and fast-growing category of regenerative aesthetics,” said Drew Taylor, MSc, PhD, CEO of Acorn Biolabs. “We’ve received incredible interest from clinics that want to bring Acorn’s personalized products into their practice as demand for regenerative aesthetics products grows. As a result, we expect our Early Access Program to be fully subscribed before the end of the year.”
“We’re thrilled to be among the first clinics in North America to offer Acorn’s groundbreaking personalized skin and hair treatments,” said Dr. Jean Carruthers, MD, FRCSC, FRC (Ophth). “It’s not often that a true innovation comes to market, and Acorn’s unique approach—preserving a patient’s healthiest, youngest cells and crafting custom products from them—represents an exciting new frontier in our field.”
Powering Acorn’s regenerative medicine platform is its cryogenic stem cell banking service, which allows people to safely store stem cells derived from their own hair follicles for their lifetime. These cells can be used in the short term to create a person’s personalized topical skin and haircare product, or in the future as personalized stem-cell therapies become available across an array of therapeutic areas. Acorn launched its stem cell banking service in North America in 2023 and is currently partnered with more than 70 clinics.
With offices in Toronto, Canada and Los Angeles, California, Acorn Biolabs is a next-generation personalized regenerative medicine company with services currently offered at partner clinic locations across North America. Acorn has developed the world’s first non-invasive, follicle-based cell cryopreservation service and has patented cell-based treatments made from a patient’s own hair follicle cells.